Latest Listings And Ipos News

Invex Therapeutics has paired its proposed acquisition of Rekover Therapeutics with a $10 million equity raising to fund a Phase 2a multiple sclerosis study and its existing Exenatide programs. The biotech ended September with A$3.59 million in cash, with shareholder approval still required for the larger part of the transaction.

Amara Minerals has reported broad gold intersections at its Apollo project in Victoria, including 102.3 metres at 2.29 g/t gold. The exploration momentum comes with just A$0.59 million in quarter-end cash and a stated need to assess further capital raising options.

Elk Range Mining’s maiden drill hole at the Friday Gold Project returned 290.3 metres at 2.8 g/t gold, including 89.6 metres at 5.5 g/t. The ASX-listed explorer is now advancing its second and third holes, with A$7.19 million in cash and further assays due late November.

Power Minerals has reported its strongest Morro do Ferro drilling results yet, alongside a conceptual 9.2 million to 10.7 million tonne Exploration Target in Brazil. But the ASX-listed explorer ended September with A$4.5 million and says it is seeking a strategic capital raising while in a trading halt.

Alterity Therapeutics says it has begun operational preparations for a Phase 3 ATH434 trial after FDA minutes confirmed the proposed design and registrational pathway in Multiple System Atrophy. The company ended September with A$41.3 million in cash, while a new US patent extends protection for ATH434 to 2045.

Great Divide Mining increased Challenger concentrate production and plant feed rates during the September quarter, but ended with A$433,000 in cash and an estimated 0.9 quarters of funding. The company is relying on higher production, cost control or potential equity funding while advancing Coonambula towards a maiden resource estimate.

Rapid Critical Metals reported expanding high-grade silver mineralisation at Webbs and strong processing test results, but ended September with $3.548 million in cash against quarterly relevant outgoings of $3.824 million. The company said it has not yet started a funding process, although it expects to consider its options.

Zicom Group delivered a third consecutive profitable year, but revenue and shareholder earnings fell sharply after major gas-processing projects were completed. The ASX-listed industrial group has strengthened its balance sheet, though dividends remain deferred while it repays an $8.72 million shareholder loan.

Paradigm Biopharmaceuticals’ pivotal knee osteoarthritis trial fell below its pre-specified continuation threshold, leaving the ASX-listed biotech in voluntary administration with A$4.33 million in cash. Administrators now have up to three months to assess restructuring options, clinical data and the company’s future.

Middle Island Resources has connected three mineralised zones at its Bobija project in Serbia into an 80,000-square-metre shallow polymetallic system, while confirming sizeable copper and gold targets elsewhere in its portfolio. The explorer is also shedding its Northern Territory licences to reduce annual commitments by about $400,000, but reported only $1.694 million in quarter-end cash.

KALiNA Power says its Alberta gas-fired generation portfolio is moving closer to commercial contracting as data centre demand, regulatory reform and grid access rules converge. The company ended the September quarter with A$11.4 million in cash, no debt and an estimated 13 quarters of funding at its current operating burn.

Alma Metals has completed 14 holes totalling 5,002.8 metres at its Briggs Copper Project, with broad copper intersections emerging as the company works towards a pre-feasibility study. The stronger drilling update comes with a funding caveat: cash alone covered an estimated 0.5 quarters of future expenditure at 30 September.